安进Amgen Inc. (AMGN) 2003年年度报告「NASDAQ」.pdf

1、What we do It starts with a flash of insight a potentially life-changing discovery.And then the really hard work begins.For more than two decades,Amgen has pursued scientific discovery and technological innovation in an effort to dramatically improve peoples lives.Cover photo taken at Amgens new sta

2、te-of-the-art research center in SeattleHarnessing the powerful tools of cellular and molecular biology and medicinal chemistry,we seek to discover,develop,and commercialize proteins,antibodies,and small molecules that can extend the reach of medicine.Its an enterprise that demands persistence,disci

3、pline,and a clear strategic approach.Breakthrough therapeutics can require years of development and hundreds of millions of dollars of investment.And there are no guarantees.Its also an accomplishment,whenachieved,that is without equal the creation of a new treatment optionwith the potential to dram

4、atically alterthe future for hundreds of thousands,even millions of patients.Striving to treat grievous illness and to improve the quality of peoples lives has become a way of life at Amgen.Its what we do.Jeremy,age ENBREL(etanercept)Michele,age Neulasta(pegfilgrastim)andAranesp(darbepoetin alfa)Ron

5、,age ENBRELServe patientsJeremy Five years ago,when Jeremy was two years old,he stoppedwalking.His doctors diagnosed systemic juvenile rheuma-toid arthritis(JRA),a form of rheumatoid arthritis that canaffect multiple body systems,often producing fever,rashes,and anemia in addition to joint pain and

6、inflammation.Jeremy has been taking ENBREL(etanercept)since,the year after it was approved for use withJRApatientsaged four to whose symptoms do not respond to otherdisease-modifying,anti-rheumatic drugs.Jeremy now ridesa scooter,plays baseball,and“acts like a regular kid,”according to his parents,K